Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

CFO Matt Abernethy projected INGREZZA sales for 2025 to range between $2.5 billion and $2.6 billion, reflecting $250 million growth at the midpoint. He noted increased competitive pressure and payer ...

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at ...

From January 2009 to January 2011, PVP surgery was conducted on 120 patients with a 120 watt green laser. Table 1 shows the basic patient data. Of all the patients, 30% took an oral anti-coagulant ...

[16] These results suggest that ejaculatory disorder caused by silodosin associated with very large improvements in patients with benign prostatic hyperplasia. On the other hand, 76% of the ...

A: an axial CT image in lung window setting reformatted in maximum intensity projection depicts multiple lung nodules (yellow arrows) in line with the diagnosis of diffuse idiopathic pulmonary ...

The fourth floor of the long-term-care hospital where I sometimes work houses patients with severe brain injuries. When I am called there to consult, I always hesitate before entering the room.

its experimental therapy for congenital adrenal hyperplasia (CAH). CAH, a group of genetic disorders affecting adrenal glands, is characterized by excessive levels of androstenedione (A4), a ...

The study enrolled 28 patients across 3 dose cohorts with ... Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome.